Standardizing the management of heparin-induced thrombocytopenia

American Journal of Health-System Pharmacy

Volumn 65, Issue 4, 2008, Pages 334-339

  Fugate, Susan ^a,b   Chiappe, Julia ^c  

^a Integris Health Anticoagulation Clinics

^b UNIVERSITY OF OKLAHOMA   (United States)

^c INTEGRIS BAPTIST MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Argatroban; Dosage; Errors; Fondaparinux; Heparin; Lepirudin; Medication; Protocols; Rational therapy; Thrombocytopenia; Toxicity

Indexed keywords

ARGATROBAN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRULOG; LEPIRUDIN; WARFARIN; ANTICOAGULANT AGENT; HIRUDIN DERIVATIVE; PIPECOLIC ACID DERIVATIVE; POLYSACCHARIDE; RECOMBINANT PROTEIN;

ANTIBODY DETECTION; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL PROTOCOL; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED PRACTICE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MEDICAL RECORD REVIEW; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STANDARDIZATION; THROMBOEMBOLISM; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE; THROMBOCYTE COUNT; THROMBOCYTOPENIA;

ANTICOAGULANTS; CLINICAL PROTOCOLS; EVIDENCE-BASED MEDICINE; HEPARIN; HIRUDINS; HUMANS; PIPECOLIC ACIDS; PLATELET COUNT; PLATELET FUNCTION TESTS; POLYSACCHARIDES; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 39549109096     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070086     Document Type: Article

References (26)

1. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation. 2005; 111:2671-83.
2. Januzzi JL Jr, Jang IK. Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. J Thromb Thrombolysis. 1999; 7:259-64.
3. Dager WE, Dougherty JA, Nguyen PH et al. Heparin-induced thrombocytopenia: treatment options and special considerations. Pharmacotherapy. 2007; 27:564-87.
4. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3, suppl):311S-37S.
5. Refludan (lepirudin) package insert. Montville, NJ: Berlex Laboratories; 2006 Nov.
6. Argatroban package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005 Jul.
7. Hassell K. The management of patients with heparin-induced thrombocytopenia who require anticoagulant therapy. Chest. 2005; 127(2, suppl):1S-8S.
8. Angiomax (bivalirudin) package insert. Parsipanny, NJ: The Medicines Company; 2005 Dec.
9. Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, eds. Heparin-induced thrombocytopenia. 2nd ed. New York: Marcel Dekker; 2001:381-407.
10. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother. 2006; 40:1383-7.
11. Greinacher A, Völpel H, Janssens U et al., for the HIT Investigators Group. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation. 1999; 99:73-80.
12. Greinacher A, Janssens U, Berg G et al., for the Heparin-Associated Thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation. 1999; 100:587-93.
13. Lubenow N, Eichler P, Lietz T et al., for the HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost. 2005; 3: 2428-36.
14. Lewis BE, Wallis DE, Berkowitz SD et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001; 103:1838-43.
15. Lewis BE, Wallis DE, Leya F et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003; 163:1849-56.
16. Lewis BE, Wallis DE, Hursting M J et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest. 2006; 129:1407-16.
17. Deitcher SR. Clinical utility of subcutaneous hirudins. Am J Health-Syst Pharm. 2003; 60(suppl 5):S27-31.
18. Begelman SM, Deitcher SR. Outpatient management of venous thromboembolic disease with subcutaneous lepirudin: a case report. J Thromb Thrombolysis. 2002; 13:183-5.
19. Huhle G, Geberth M, Hoffmann U et al. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest. 2000; 49:67-9.
20. Huhle G, Hoffmann U, Hoffmann I et al. A new therapeutic option for subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb Res. 2000; 99:325-34.
21. Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost. 2005; 93:999-1000.
22. Rubin N, Rubin J. Treatment of heparin-induced thrombocytopenia with thrombosis (HITT) in pregnancy with fondaparinux. Blood. 2003; 102:4190. Abstract.
23. Bradner J, Hallisey RK, Kuter DJ. Fondaparinux in the treatment of heparin-induced thrombocytopenia. Blood. 2004; 104:1775. Abstract.
24. Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica. 2004; 89:1017-8.
25. Parody R, Oliver A, Souto JC et al. Fondaparinux (Arixtra) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. www.haematologica.org/cgi/reprint/ 88/11/ECR32 (accessed 2006 May 23).
26. Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother. 2006; 40:1383-7.